Monday February 18, 2019

People infected with the hepatitis C may also suffer from heart trouble

0
//
drmadadi.rhc.ac.ir

New York: People infected with the hepatitis C virus are already known to be at risk for liver damage, and results of a new study now shows that the infection may also spell heart trouble.

Hepatitis C Blood Virus [HCV]. Photo Credit: michelsonmedical.org
Hepatitis C Blood Virus [HCV]. Photo Credit: michelsonmedical.org
“People infected with hepatitis C are already followed regularly for signs of liver disease, but our findings suggest clinicians who care for them should also assess their overall cardiac risk profile regularly,” said study author Wendy Post, professor of medicine at the Johns Hopkins University School of Medicine in Baltimore, Maryland, US.

Although HIV and hepatitis C infections often occur together and people infected with HIV are already known to have an elevated risk for heart disease, the new study offers strong evidence that hepatitis C can spark cardiovascular damage independent of HIV.

“We have strong reason to believe that infection with hepatitis C fuels cardiovascular disease, independent of HIV and sets the stage for subsequent cardiovascular trouble,” study principal investigator Eric Seaberg, assistant professor at the Johns Hopkins Bloomberg School of Public Health, noted.

“We believe our findings are relevant to anyone infected with hepatitis C regardless of HIV status,” Seaberg pointed out.

The study involved 994 men 40 to 70-years old without overt heart disease.

Of the 994,613 were infected with HIV, 70 were infected with both viruses and 17 were only infected with hepatitis C.

Those infected with hepatitis C, regardless of HIV status, had, on average, 30 percent more disease-fueling calcified plaque in their arteries, the main driver of heart attack and stroke risk.

People infected with either HIV or hepatitis C, on average, had 42 percent more non-calcified fatty buildup, a type of plaque believed to confer the greatest cardiac risk.

The study appeared in The Journal of Infectious Diseases.

(IANS)

Next Story

The World Looks Forward To Eradication Of Hepatitis C By 2030

Offering direct-acting antivirals to all patients at the time of diagnosis could prevent 640,000 deaths from liver cancer and cirrhosis by 2030

0
the new Hepatitis B vaccine for adults is called Heplisav-B.
The team found that implementing comprehensive blood safety and infection control measures was estimated to reduce the number of new infections in 2030 by 58 per cent.

Improvements in screening, prevention and treatment particularly in high-burden countries, such as India, China and Pakistan, can avert 15.1 million new hepatitis C infections and 1.5 million cirrhosis and liver cancer deaths globally by 2030.

Globally, it is estimated that 71 million individuals are chronically infected with the hepatitis C virus, that attacks the liver and leads to inflammation.

The virus was also responsible for over 475,000 deaths in 2015.

Viral hepatitis
World Health Organization poster for Hepatitis Campaign. VOA

To achieve the big reductions, there is need to implement comprehensive blood safety and infection control measures, extend harm reduction services (such as opioid substitution therapy and needle and syringe programmes) and replace older treatments with direct-acting antivirals in all countries.

Moreover, adding screening to these interventions can help diagnose 90 per cent of people with hepatitis C and offer treatment by 2030, according to the study published in The Lancet journal.

The estimates equal to an 80 per cent reduction in incidence and a 60 per cent reduction in deaths as compared to 2015.

Injection and medicines
Hepatitis are the commonly transmitted hepatotropic viruses transmitted due to poor hygiene, contaminated food and drinking water, poor sanitation, Pixabay

But, it narrowly misses the elimination targets set by the World Health Organisation (WHO) — to reduce mortality by 65 per cent — and would instead be attained by 2032, the researchers said.

“Even though it narrowly falls short of the WHO targets for 2030, the impact our estimates suggest would be a tremendous stride forwards,” said lead author Professor Alastair Heffernan, from UK’s Imperial College London.

The team found that implementing comprehensive blood safety and infection control measures was estimated to reduce the number of new infections in 2030 by 58 per cent.

Hepatitis C Blood Virus [HCV]. Photo Credit: michelsonmedical.org
Extending harm reduction services to 40 per cent of people who inject drugs could reduce the number of new infections by a further 7 percentage points.

Together, this would prevent 14.1 million new infections by 2030.

But, offering direct-acting antivirals to all patients at the time of diagnosis could prevent 640,000 deaths from liver cancer and cirrhosis by 2030, the researchers noted.

Also Read: Major Breakthrough Made In The Treatment Of Ebola Virus

“Achieving such reductions requires a massive screening programme and demands a rapid increase in new treatment courses in the short term — namely, 51.8 million courses of direct-acting antivirals by 2030,” Heffernan said. (IANS)